Research and Development Costs of New Drugs - Reply

被引：11
|
作者：
Wouters, Olivier J. [1 ]
McKee, Martin [2 ]
Luyten, Jeroen [3 ]
机构：
[1] London Sch Econ & Polit Sci, Dept Hlth Policy, Houghton St, London WC2A 2AE, England
[2] London Sch Econ & Polit Sci, Dept Hlth Serv Res & Policy, London, England
[3] Leuven Inst Healthcare Policy, Dept Publ Hlth & Primary Care, Leuven, Belgium
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2020年 / 324卷 / 05期
关键词：
D O I：
10.1001/jama.2020.8651
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：517 / 518
页数：2
相关论文
共 50 条
  • [21] ACCOUNTING FOR RESEARCH AND DEVELOPMENT COSTS
    BIERMAN, H
    DUKES, RE
    JOURNAL OF ACCOUNTANCY, 1975, 139 (04): : 48 - 55
  • [22] CONTROL OF RESEARCH AND DEVELOPMENT COSTS
    QUINN, JB
    JOURNAL OF ACCOUNTANCY, 1960, 110 (04): : 51 - 58
  • [23] RESEARCH AND DEVELOPMENT OF NEW CONCEPTS HELPS KEEP PRODUCTION COSTS DOWN
    GALLAY, W
    PULP AND PAPER MAGAZINE OF CANADA, 1970, 71 (01): : 30 - &
  • [24] Pricing of Drugs With Evidence Development In Reply
    Robinson, James C.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2022, 328 (08): : 778 - 778
  • [25] ANTIEPILEPTIC DRUGS AND DEVELOPMENT OF RICKETS - IN REPLY
    BORGSTEDT, AD
    BRYSON, MF
    YOUNG, LW
    FORBES, GB
    JOURNAL OF PEDIATRICS, 1973, 82 (02): : 348 - 348
  • [26] Development and evaluation committees' methods for appraising new drugs - Reply by members of committee
    Campbell, B
    Stein, K
    Milne, R
    BRITISH MEDICAL JOURNAL, 2000, 320 (7236): : 715 - 715
  • [27] ACCOUNTING FOR RESEARCH AND DEVELOPMENT COSTS - THE IMPACT ON RESEARCH AND DEVELOPMENT EXPENDITURES
    DUKES, RE
    DYCKMAN, TR
    ELLIOTT, JA
    JOURNAL OF ACCOUNTING RESEARCH, 1980, 18 : 1 - 26
  • [28] Drugs firms inflate research costs, watchdog says
    Jonathan Knight
    Nature, 2001, 412 : 571 - 571
  • [29] Drugs firms inflate research costs, watchdog says
    Knight, J
    NATURE, 2001, 412 (6847) : 571 - 571
  • [30] The costs and benefits of regulations for reimbursement of new drugs
    Lundkvist, Jonas
    Jonsson, Bengt
    Rehnberg, Clas
    HEALTH POLICY, 2006, 79 (2-3) : 337 - 344
12345